How a Drug Company Made $114 Billion by Gaming the U.S. Patent System

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end. In 2016, a blockbuster drug called Humira was poised to become a lot less valuable. The key patent on the best-selling anti-inflammatory medication, used to…#humira #abbvie #amgensamjevita #ssrhealth #medicare #bristolmyerssquibb #astrazeneca #rachelsachs #washingtonuniversity #stlouis

Source: Reuters: Health - January 28, 2023 Category: Consumer Health News Source Type: news